ネパフェナク
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/03/31 16:39:13」(JST)
[Wiki en表示]
Nepafenac
|
| Systematic (IUPAC) name |
| 2-amino-3-benzoylbenzeneacetamide |
| Clinical data |
| Trade names |
Nevanac |
| AHFS/Drugs.com |
monograph |
| MedlinePlus |
a606007 |
|
Pregnancy
category
|
|
|
Legal status
|
|
|
Routes of
administration
|
Ophthalmic |
| Identifiers |
|
ATC code
|
S01BC10 |
| PubChem |
CID 151075 |
| DrugBank |
DB06802 Y |
| ChemSpider |
133160 Y |
| UNII |
0J9L7J6V8C Y |
| KEGG |
D05143 Y |
| ChEBI |
CHEBI:75922 N |
| ChEMBL |
CHEMBL1021 Y |
| Chemical data |
| Formula |
C15H14N2O2 |
|
Molecular mass
|
254.28 g/mol |
SMILES
- O=C(c1cccc(c1N)CC(=O)N)c2ccccc2
|
InChI
-
InChI=1S/C15H14N2O2/c16-13(18)9-11-7-4-8-12(14(11)17)15(19)10-5-2-1-3-6-10/h1-8H,9,17H2,(H2,16,18) Y
Key:QEFAQIPZVLVERP-UHFFFAOYSA-N Y
|
| N (what is this?) (verify) |
Nepafenac is a non-steroidal anti-inflammatory drug (NSAID), usually sold as a prescription eye drop 0.1% solution. Nepafenac is manufactured by Alcon and sold under the trade name Nevanac. It is used to treat pain and inflammation associated with cataract surgery.[1]
The usual dose is one drop, thrice a day, in each affected eye beginning one day prior to cataract surgery, continued on the day of surgery and through the first two weeks of the postoperative period.[1]
Nepafenac is a prodrug of amfenac, an inhibitor of COX-1 and COX-2 activity.[2][3] Its side effects may include decreased visual acuity, a feeling that something is in the eye, increased eye pressure or a sticky sensation, as well as other effects.[1]
References
- ^ a b c Nepafenac monograph
- ^ Drugbank: Nepafenac
- ^ Lira, R. P.; Fulco, E. A.; Chaves, A.; Da Costa Pinto, F.; Arieta, F. R.; Lira, C. E. (2012). "Effect of preoperative use of topical prednisolone acetate, ketorolac tromethamine, nepafenac and placebo, on the maintenance of intraoperative mydriasis during cataract surgery: A randomized trial". Indian Journal of Ophthalmology 60 (4): 277–281. doi:10.4103/0301-4738.98705. PMC 3442462. PMID 22824596. edit
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- A novel pH-induced thermosensitive hydrogel composed of carboxymethyl chitosan and poloxamer cross-linked by glutaraldehyde for ophthalmic drug delivery.
- Yu S1, Zhang X1, Tan G1, Tian L1, Liu D2, Liu Y1, Yang X3, Pan W4.
- Carbohydrate polymers.Carbohydr Polym.2017 Jan 2;155:208-217. doi: 10.1016/j.carbpol.2016.08.073. Epub 2016 Aug 25.
- In this work, a stimuli-responsive three dimensional cross-linked hydrogel system containing carboxymethyl chitosan (CMC) and poloxamer composed of a poly (ethylene oxide)/poly (propylene oxide)/poly (ethylene oxide) (PEO-PPO-PEO) block copolymer was constructed, and its aqueous solution was found t
- PMID 27702506
- Prophylactic non-steroidal anti-inflammatory drugs for the prevention of macular oedema after cataract surgery.
- Lim BX1, Lim CH, Lim DK, Evans JR, Bunce C, Wormald R.
- The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2016 Nov 1;11:CD006683.
- BACKGROUND: Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with spontaneous res
- PMID 27801522
- Comparison of the Tolerability of Diclofenac and Nepafenac.
- Achiron A1,2, Karmona L1,2, Mimouni M3, Gershoni A2,4, Dzhanov Y1,2, Gur Z5, Burgansky Z1,2.
- Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.J Ocul Pharmacol Ther.2016 Nov;32(9):601-605. Epub 2016 Aug 11.
- PURPOSE: Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the prevention and treatment of inflammation and pain following cataract surgery. Preservative-free diclofenac and nepafenac drops are commonly used ophthalmic NSAIDs. The purpose of this study was to compare the tole
- PMID 27513223
Japanese Journal
- 私の経験 白内障術後炎症管理におけるnepafenac 0.1%点眼使用経験
- 白内障術後のネパフェナク点眼が角膜上皮に及ぼす影響 (第69回日本臨床眼科学会講演集(2))
- ネパフェナク懸濁性点眼液0.1%の眼科手術後の炎症および眼痛に対する第III相臨床試験
Related Links
- Buy Nepafenac (CAS 78281-72-8 Welcome to Santa Cruz Biotechnology! ログイン | 0 Items in Cart | Quick Order Follow @SantaCruzBio Genome Search Research Products Primary Antibodies: Mammalian リン酸化型特異的抗体 ...
- Nepafenac official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. ... Increased Bleeding Time With some nonsteroidal anti-inflammatory drugs including ...
★リンクテーブル★
[★]
- 英
- nepafenac
- 商
- ネバナック
- 関
- 眼科用剤